⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148521 | 0.76 | LAP3 (0.36) | — | |
| SCHEMBL2148429 | 0.74 | ANPEP (0.39) | — | |
| SCHEMBL2148324 | 0.68 | GABBR2 (0.42) | — | |
| SCHEMBL2148484 | 0.68 | ANPEP (0.33) | — | |
| SCHEMBL2148512 | 0.66 | GABBR2 (0.36) | — | |
| SCHEMBL2148435 | 0.65 | ALDH1A1 (0.34) | — | |
| SCHEMBL2148486 | 0.65 | GABBR2 (0.35) | — | |
| SCHEMBL2430320 | 0.65 | — | — | |
| SCHEMBL2148523 | 0.64 | ANPEP (0.38) | — | |
| SCHEMBL21658659 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090312-A1 | METHODS OF USE RELATED TO XEROSTOMIA | MEDIMMUNE LLC (US) | 2013-04-11 | — | — | US | disclosed |
| US-20110166108-A1 | METHODS OF USE RELATED TO XEROSTOMIA | MEDIMMUNE, LLC. | 2011-07-07 | — | — | US | disclosed |
| US-7629333-B2 | Stable amorphous amifostine compositions and methods for the preparation and use of same | MEDIMMUNE, LLC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080027030-A1 | Pharmaceutical compositions comprising amifostine and related compounds | STOGNIEW MARTIN | 2008-01-31 | — | — | US | disclosed |
| EP-1764103-A2 | Crystalline amifostine compositions and methods for the preparation and use of same | Medimmune Oncology, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7151094-B2 | Topical administration of amifostine and related compounds | MEDLMMUNE ONCOLOGY, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060270636-A1 | Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds | MEDIMMUNE ONCOLOGY, INC. | 2006-11-30 | — | — | US | disclosed |
| US-7105575-B2 | Methods for the treatment of neuro- disorders using aminothiol compounds | MEDIMMUNE ONCOLOGY INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1039887-B1 | USE OF AMINOTHIOL COMPOUNDS FOR THE TREATMENT OF NEURO- AND NEPHRO-DISORDERS AND THERAPEUTIC TOXICITIES | MEDIMMUNE ONCOLOGY INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060040903-A1 | Methods of use related to xerostomia | STOGNIEW MARTIN | 2006-02-23 | — | — | US | disclosed |
| US-20020010357-A1 | STABLE AMORPHOUS AMIFOSTINE COMPOSITIONS AND DOSAGE FORM | CLINIGEN GROUP PLC (GB) | 2002-01-24 | — | — | US | disclosed |
| EP-1131103-A1 | STABLE AMORPHOUS AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6239119-B1 | PROTECTING MUCOSAL TISSUE FROM DAMAGE ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPEUTIC TREATMENT OF CANCERS, AVOID THE SIDE EFFECTS OF SYSTEMICALLY APPLIED RADIO/CHEMO PROTECTANTS. | MEDIMMUNE ONCOLOGY, INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1039887-A1 | METHODS FOR TREATMENT OF NEURO- AND NEPHRO-DISORDERS AND THERAPEUTIC TOXICITIES USING AMINOTHIOL COMPOUNDS | U.S. BIOSCIENCE, INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000029025-A1 | STABLE AMORPHOUS AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 2000-05-25 | — | — | WO | disclosed |
| US-5994409-A | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds | U.S. BIOSCIENCE, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999029312-A1 | METHODS FOR TREATMENT OF NEURO- AND NEPHRO-DISORDERS AND THERAPEUTIC TOXICITIES USING AMINOTHIOL COMPOUNDS | U.S. BIOSCIENCE, INC. (US) | 1999-06-17 | — | — | WO | disclosed |
| US-5591731-A | Crystalline amifostine compositions | U.S. BIOSCIENCE, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5424471-A | Stabilizing the drug for storage stability, heat resistance by hydrating in an alcohol water solution, vacuum drying to form solid crystals | U.S. BIOSCIENCE, INC. (US) | 1995-06-13 | — | — | US | disclosed |
| WO-1994003179-A1 | CRYSTALLINE AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 1994-02-17 | — | — | WO | disclosed |